Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AbbVie Inc

ABBV
Current price
175.75 USD -0.08 USD (-0.05%)
Last closed 177.49 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 309 799 288 832 USD
Yield for 12 month +16.65 %
1Y
3Y
5Y
10Y
15Y
ABBV
21.11.2021 - 28.11.2021

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

166.35 USD

P/E ratio

64.511

Dividend Yield

3.53 %

Current Year

+58 054 000 000 USD

Last Year

+56 197 000 000 USD

Current Quarter

+13 927 000 000 USD

Last Quarter

+13 865 000 000 USD

Current Year

+40 640 000 000 USD

Last Year

+38 751 000 000 USD

Current Quarter

+7 442 000 000 USD

Last Quarter

+9 625 000 000 USD

Key Figures ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 26 254 331 904 USD
Operating Margin TTM 31.46 %
PE Ratio 64.511
Return On Assets TTM 8.65 %
PEG Ratio 1.6372
Return On Equity TTM 33.13 %
Wall Street Target Price 166.35 USD
Revenue TTM 54 317 998 080 USD
Book Value 6.85 USD
Revenue Per Share TTM 30.64 USD
Dividend Share 5.99 USD
Quarterly Revenue Growth YOY -5.4 %
Dividend Yield 3.53 %
Gross Profit TTM 41 527 000 000 USD
Earnings Share 2.72 USD
Diluted Eps TTM 2.72 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -66.8 %
Profit Margin 8.95 %

Dividend Analytics ABBV

Champion - 10+ consecutive years of dividend increases

Dividend growth over 5 years

106 %

Continuous growth

10 years

Payout Ratio 5 years average

106 %

Dividend History ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 6.2
Ex Dividend Date 12.04.2024
Forward Annual Dividend Yield 3.53 %
Last Split Factor
Payout Ratio 53.92 %
Last Split Date
Dividend Date 15.05.2024

Stock Valuation ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 64.511
Forward PE 15.5521
Enterprise Value Revenue 6.5699
Price Sales TTM 5.7044
Enterprise Value EBITDA 26.3659
Price Book MRQ 29.9511

Financials ABBV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ABBV

For 52 weeks

127.03 USD 178.92 USD
50 Day MA 162.72 USD
Shares Short Prior Month 12 084 497
200 Day MA 148.54 USD
Short Ratio 2.57
Shares Short 13 718 240
Short Percent 0.78 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

402.79 USD Microsoft Corporation -0.45 (-0.11%)
Detailed analytics

ETF funds


S

SX7EEX

11.59 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2031.07 USD Gold +9.2 (+0.46%)
Detailed analytics